A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

BACKGROUND: Crohn's disease (CD) is a severe, lifelong disease characterised by inflammation of the gastrointestinal mucosa. The impact on patients and society is high as ill health can be lifelong and can negatively affect patients' quality of life. Costs to the NHS are high, particularly...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Health Technol Assess
Main Authors: Dretzke, J, Edlin, R, Round, J, Connock, M, Hulme, C, Czeczot, J, Fry-Smith, A, McCabe, C, Meads, C
Formato: Artigo
Idioma:Inglês
Publicado: NIHR Journals Library 2011
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781107/
https://ncbi.nlm.nih.gov/pubmed/21291629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta15060
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares